NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

May 17, 2024

Study Completion Date

May 17, 2026

Conditions

CRCSolid Tumor

Interventions

BIOLOGICAL

KD-025

Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Trial Locations (1)

RECRUITING

Chinese PLA General Hospital, Beijing

All Listed Sponsors

collaborator

KAEDI

OTHER

lead

jianming xu

OTHER